N/A N=60 Neurophysiological Targets for Cognitive Training in Schizophrenia
Schizophrenia
Primary: Visual Target Detection (P300 Event-related Potential Amplitude) Change — 2.20; -0.72 microvolts (uV) — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=71 Multicenter Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Retreatment
Nasolabial Fold Correction
Primary: Change in the Wrinkle Severity Rating Scale (WSRS) With Subjects From Both the Retreatment and the Optimal Correction Groups - WSRS Scores at Visit 8/Week 52 — 0.1; 0.6…
Phase 2 N=90 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
Phase 1 N=12 RDEA3170 and Allopurinol Combination Study in Gout Subjects
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 1.13; 1.51; 12.8; 8.68 μg/mL
Phase 2 N=35 Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?
Smoking
Primary: Latency (Min) to Initiate Ad-lib Smoking Session — 11.304; 32.128; 27.557; 23.474 minutes
Phase 3 N=56 Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Kidney Failure, Chronic
Primary: 6-month Acute Cellular-mediated Rejection Rate (CMR) — 14; 20 Participants
N/A N=60 Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion
Stenosis · Spondylosis · Degenerative Changes
Primary: Number of Levels With Posterolateral Fusion — 23; 26 levels
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Phase 2 N=183 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24 — 59.9; 39.2; 40.1 Percentage of participants — p=0.076
Phase 2 N=49 Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana
Marijuana Use
Primary: Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose. — 8.0; 25.0; 6.7; 34.0 units on a scale
N/A N=54 Acute and Chronic Nicotine Modulation of Reinforcement Learning
Nicotine Addiction
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signal in Dorsomedial Prefrontal Cortex — 7.3; 6.3; 6.2; .02 percentage of BOLD signal
N/A N=136 Louisiana State University Health Care Sciences Division (LSU HSCD) Tele-Health Projects: Adult CHF Patient Population
Congestive Heart Failure
Primary: Events Per Person-year — 84; 57 events/person-year — p=0.094
N/A N=37 Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study
Myocardial Ischemia
Primary: Inducible Myocardial Ischemia — -13.8; -7.0 percent changed in PCR/ATP ratio — p=0.36
N/A N=10 The Effects of Light Therapy on Circadian Rhythms, Sleep, and Mood in Postpartum Depression
Depression, Postpartum
Primary: Change From Baseline Score of the Hamilton Depression Rating Scale-Seasonal Affective Version (SIGH-SAD) at 5 Weeks — 24.75; 12.88 SIGH-SAD score — p=.001
Phase 1 N=36 AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol
Healthy
Primary: Comparative Evaluation of Ethinyl Estradiol (EE) Cmax Between AG200-15 and Ortho-Cyclen® in Week 1 — 135; 45.5 pg/ml — p=<0.0001